BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 33119477)

  • 21. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
    Schmoll HJ; Stein A; Van Cutsem E; Price T; Hofheinz RD; Nordlinger B; Daisne JF; Janssens J; Brenner B; Reinel H; Hollerbach S; Caca K; Fauth F; Hannig CV; Zalcberg J; Tebbutt N; Mauer ME; Marreaud S; Lutz MP; Haustermans K
    J Clin Oncol; 2021 Jan; 39(1):17-29. PubMed ID: 33001764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
    BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
    McWilliams RR; Foster NR; Mahoney MR; Smyrk TC; Murray JA; Ames MM; Horvath LE; Schneider DJ; Hobday TJ; Jatoi A; Meyers JP; Goetz MP
    Cancer; 2017 Sep; 123(18):3494-3501. PubMed ID: 28493308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
    Klautke G; Küchenmeister U; Foitzik T; Ludwig K; Prall F; Klar E; Fietkau R
    Br J Cancer; 2006 Apr; 94(7):976-81. PubMed ID: 16552435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
    Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
    J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
    de las Heras M; Arias F; del Moral-Avila R; Gómez-Millán J; Jiménez E; Wals A; Tisaire JL; Alcantara MP
    Clin Transl Oncol; 2013 Apr; 15(4):294-9. PubMed ID: 22855196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
    Horisberger K; Treschl A; Mai S; Barreto-Miranda M; Kienle P; Ströbel P; Erben P; Woernle C; Dinter D; Kähler G; Hochhaus A; Post S; Willeke F; Wenz F; Hofheinz RD;
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1487-93. PubMed ID: 19131187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
    Kim JS; Kim JS; Cho MJ; Song KS; Yoon WH
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):403-8. PubMed ID: 12243814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.
    Leichman CG; McDonough SL; Smalley SR; Billingsley KG; Lenz HJ; Beldner MA; Hezel AF; Velasco MR; Guthrie KA; Blanke CD; Hochster HS
    Clin Colorectal Cancer; 2018 Mar; 17(1):e121-e125. PubMed ID: 29233486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
    Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
    Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
    Wang J; Guan Y; Gu W; Yan S; Zhou J; Huang D; Tong T; Li C; Cai S; Zhang Z; Zhu J
    Radiat Oncol; 2019 Nov; 14(1):215. PubMed ID: 31783766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
    Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Laffay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Montoto-Grillot C; Conroy T
    J Clin Oncol; 2010 Apr; 28(10):1638-44. PubMed ID: 20194850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
    Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
    Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    Malik I; Hussein F; Bush D; Alqaisi M; Bernal P; Byrd J; Garberoglio C
    Am J Clin Oncol; 2010 Jun; 33(3):242-5. PubMed ID: 19806036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
    Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.